Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars G Hemkens

Showing results (81-90 of 143) with videos related to

Pageof 15
Sort By:
ESMO Open|December 6, 2019
Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU projectAmanda Katherina Herbrand, Andreas Michael Schmitt, Matthias Briel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 22, 2024
Use of pragmatic randomized trials in multiple sclerosis: A systematic overviewJulian Hirt, Perrine Janiaud, Pascal Düblin, et al.
Addiction (Abingdon, England)|February 9, 2025
Relative risks of adverse effects across different opioid agonist treatments-A systematic review and meta-analysisMaximilian Meyer, Eriks Strazdins, Adrian Guessoum, et al.
BMJ Open|October 28, 2025
Mixed-methods process evaluation of ctDNA use to guide decision-making in patients with advanced solid cancers: study protocol for a substudy of the LIQPLAT trialJohannes M Schwenke, Andreas M Schmitt, Stuart McLennan, et al.
Journal of Clinical Epidemiology|August 12, 2020
Abbreviated and comprehensive literature searches led to identical or very similar effect estimates: a meta-epidemiological studyHannah Ewald, Irma Klerings, Gernot Wagner, et al.
Trials|September 21, 2018
The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugsAviv Ladanie, Benjamin Speich, Florian Naudet, et al.
International Journal of Cancer|February 13, 2023
The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020Viktoria Gloy, Andreas M Schmitt, Pascal Düblin, et al.
Journal of Clinical Epidemiology|May 5, 2023
GRADE concept 4: rating the certainty of evidence when study interventions or comparators differ from PICO targetsMarius Goldkuhle, Gordon H Guyatt, Nina Kreuzberger, et al.
JAMA|February 26, 2021
Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysisPerrine Janiaud, Cathrine Axfors, Andreas M Schmitt, et al.
Journal of Clinical Epidemiology|September 14, 2021
Reporting transparency and completeness in trials: Paper 3 - trials conducted using administrative databases do not adequately report elements related to use of databasesMahrukh Imran, Kimberly Mc Cord, Stephen J McCall, et al.
Pageof 15

Showing results (81-90 of 143) with videos related to

Sort By:
Pageof 15
ESMO Open|December 6, 2019
Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU projectAmanda Katherina Herbrand, Andreas Michael Schmitt, Matthias Briel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 22, 2024
Use of pragmatic randomized trials in multiple sclerosis: A systematic overviewJulian Hirt, Perrine Janiaud, Pascal Düblin, et al.
Addiction (Abingdon, England)|February 9, 2025
Relative risks of adverse effects across different opioid agonist treatments-A systematic review and meta-analysisMaximilian Meyer, Eriks Strazdins, Adrian Guessoum, et al.
BMJ Open|October 28, 2025
Mixed-methods process evaluation of ctDNA use to guide decision-making in patients with advanced solid cancers: study protocol for a substudy of the LIQPLAT trialJohannes M Schwenke, Andreas M Schmitt, Stuart McLennan, et al.
Journal of Clinical Epidemiology|August 12, 2020
Abbreviated and comprehensive literature searches led to identical or very similar effect estimates: a meta-epidemiological studyHannah Ewald, Irma Klerings, Gernot Wagner, et al.
Trials|September 21, 2018
The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugsAviv Ladanie, Benjamin Speich, Florian Naudet, et al.
International Journal of Cancer|February 13, 2023
The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020Viktoria Gloy, Andreas M Schmitt, Pascal Düblin, et al.
Journal of Clinical Epidemiology|May 5, 2023
GRADE concept 4: rating the certainty of evidence when study interventions or comparators differ from PICO targetsMarius Goldkuhle, Gordon H Guyatt, Nina Kreuzberger, et al.
JAMA|February 26, 2021
Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysisPerrine Janiaud, Cathrine Axfors, Andreas M Schmitt, et al.
Journal of Clinical Epidemiology|September 14, 2021
Reporting transparency and completeness in trials: Paper 3 - trials conducted using administrative databases do not adequately report elements related to use of databasesMahrukh Imran, Kimberly Mc Cord, Stephen J McCall, et al.
Pageof 15